QIAGEN Appoints Chief Medical Officer
Ellen Sheets to lead the company's biomarker discovery strategy and its evaluation program for new molecular diagnostic content
Germantown, Md. and Hilden, Germany - July 8, 2010 - QIAGEN today announced that Dr. Ellen E. Sheets has joined the company as Chief Medical Officer, effective July 6, 2010. In her new role, Dr. Sheets will be primarily responsible for the development of QIAGEN's strategy for the discovery of biomarkers for new cancer diagnostics and their timely and effective clinical evaluation. Dr. Sheets will be located at the Gaithersburg, MD, site and will report to Dr. Joachim Schorr, Senior Vice President Global R&D.
Dr. Sheets has a strong track record in clinical trial and product development and brings to QIAGEN a wealth of experience from leading positions previously held in academia and the diagnostics industry. As an Associate Professor at Harvard Medical School she built a successful gynecologic oncology practice and developed cervical cancer research programs. She also served on numerous U.S. Committees (including gynecologic cancer subcommittee work for the NCI) and acted as a consultant to the FDA. As Vice President Clinical Affairs and later Chief Medical Officer for Hologic Inc., Dr. Sheets was instrumental in growing top-line revenues from US$250 million to over US$750 million. She joins QIAGEN from Predictive Biosciences, where she successfully headed the development of a novel marker business as General Manager and Chief Medical Officer. Dr. Sheets holds a B.A. and an M.D. degree from the University of Michigan and earned a M.B.A. from the Stern School at New York University. In addition to her biomarker development and evaluation program responsibilities, Dr. Sheets will assume leadership for the cross-functional content portfolio team, provide medical and regulatory expertise and ensure a consistent approach to key opinion leader relationship building.
"We are extremely pleased to welcome Ellen to our team", said Dr. Joachim Schorr, QIAGEN's Senior Vice President, Global R&D. "With her rich expertise she will help leverage QIAGEN's capabilities to discover and validate new biomarkers, strengthen our position as a premium partner for biomedical and pharmaceutical institutions and generate new content for all segments of molecular diagnostics: prevention, profiling, personalized healthcare and point-of-need testing.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.